<VariationArchive VariationID="583641" VariationName="NC_000016.9:g.(?_3799608)_(3821007_?)dup" VariationType="Duplication" Accession="VCV000583641" Version="8" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="1" DateLastUpdated="2024-06-17" DateCreated="2018-10-10" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="573660" VariationID="583641">
      <GeneList>
        <Gene Symbol="CREBBP" FullName="CREB binding protein" GeneID="1387" HGNC_ID="HGNC:2348" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>16p13.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" start="3725054" stop="3880713" display_start="3725054" display_stop="3880713" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" start="3775054" stop="3930120" display_start="3775054" display_stop="3930120" Strand="-" />
          </Location>
          <OMIM>600140</OMIM>
          <Haploinsufficiency last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2019-10-23" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CREBBP">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NC_000016.9:g.(?_3799608)_(3821007_?)dup</Name>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>16p13.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="16" Accession="NC_000016.10" innerStart="3749607" innerStop="3771006" display_start="3749607" display_stop="3771006" variantLength="21400" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="16" Accession="NC_000016.9" innerStart="3799608" innerStop="3821007" display_start="3799608" display_stop="3821007" variantLength="21400" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000016.9" sequenceAccession="NC_000016" sequenceVersion="9" change="g.(?_3799608)_(3821007_?)dup" Assembly="GRCh37">
            <Expression>NC_000016.9:g.(?_3799608)_(3821007_?)dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000016.9:g.(?_3799608)_(3821007_?)dup AND Rubinstein-Taybi syndrome due to CREBBP mutations" Accession="RCV000707927" Version="1">
        <ClassifiedConditionList TraitSetID="1898">
          <ClassifiedCondition DB="MedGen" ID="C4551859">Rubinstein-Taybi syndrome due to CREBBP mutations</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-04-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NC_000016.9:g.(?_3799608)_(3821007_?)dup AND Rubinstein-Taybi syndrome" Accession="RCV001380926" Version="7">
        <ClassifiedConditionList TraitSetID="46378">
          <ClassifiedCondition DB="MedGen" ID="C0035934">Rubinstein-Taybi syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2018-04-03" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2018-04-05" NumberOfSubmissions="2" NumberOfSubmitters="1" DateCreated="2018-10-10" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">17052327</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">18792986</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">25640679</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="46378" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="41364" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome</ElementValue>
                <XRef ID="Rubinstein-Taybi+syndrome/6372" DB="Genetic Alliance" />
                <XRef ID="MONDO:0019188" DB="MONDO" />
                <XRef Type="Phenotypic series" ID="PS180849" DB="OMIM" />
                <XRef ID="45582004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Broad thumb-hallux syndrome</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS1</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Preferred">RSTS</ElementValue>
                <XRef Type="MIM" ID="180849" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="7593" />
                <XRef ID="7593" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C0035934" DB="MedGen" />
              <XRef ID="MONDO:0019188" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS180849" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1898" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="4360" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Rubinstein-Taybi syndrome 1</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Rubinstein syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Broad thumbs and great toes, characteristic facies, and mental retardation</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Preferred">Rubinstein-Taybi syndrome due to CREBBP mutations</ElementValue>
                <XRef ID="MONDO:0008393" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">RUBINSTEIN-TAYBI SYNDROME 1, INCOMPLETE</ElementValue>
                <XRef Type="Allelic variant" ID="600140.0008" DB="OMIM" />
                <XRef Type="Allelic variant" ID="600140.0005" DB="OMIM" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">RSTS1</ElementValue>
                <XRef Type="MIM" ID="180849" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">RTS</ElementValue>
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">CREBBP</ElementValue>
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Rubinstein-Taybi syndrome (RSTS) is characterized by distinctive facial features, broad and often angulated thumbs and halluces, short stature, and moderate-to-severe intellectual disability. The characteristic craniofacial features are downslanted palpebral fissures, low-hanging columella, high palate, grimacing smile, and talon cusps. Prenatal growth is often normal, then height, weight, and head circumference percentiles rapidly drop in the first few months of life. Short stature is typical in adulthood. Obesity may develop in childhood or adolescence. Average IQ ranges between 35 and 50; however, developmental outcome varies considerably. Some individuals with EP300-RSTS have normal intellect. Additional features include ocular abnormalities, hearing loss, respiratory difficulties, congenital heart defects, renal abnormalities, cryptorchidism, feeding problems, recurrent infections, and severe constipation.</Attribute>
                <XRef ID="NBK1526" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">CREBBP-Related Rubinstein-Taybi Syndrome</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="17534" />
                <XRef ID="17534" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301699</ID>
                <ID Source="BookShelf">NBK1526</ID>
              </Citation>
              <XRef ID="353277" DB="Orphanet" />
              <XRef ID="783" DB="Orphanet" />
              <XRef ID="C4551859" DB="MedGen" />
              <XRef ID="MONDO:0008393" DB="MONDO" />
              <XRef Type="MIM" ID="180849" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="1609062" SubmissionDate="2018-08-29" DateLastUpdated="2018-10-10" DateCreated="2018-10-10">
        <ClinVarSubmissionID localKey="3738193|MedGen:C0035934" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV000837037" DateUpdated="2018-10-10" DateCreated="2018-10-10" Type="SCV" Version="1" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant results in a copy number gain of the genomic region encompassing exons 14-21 of the CREBBP gene. While the exact position of this variant cannot be determined from this data, sub-genic copy number gains are generally in tandem (PMID: 25640679) and may result in an absent or disrupted protein product. This copy number gain has been observed to be de novo in an individual affected with clinical features of Rubinstein-Taybi syndrome (Invitae). Loss-of-function variants in CREBBP are known to be pathogenic (PMID: 17052327, 18792986). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CREBBP" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_3799608)_(3821007_?)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">Rubinstein-Taybi syndrome</ElementValue>
            </Name>
            <XRef DB="MedGen" ID="C0035934" Type="CUI" />
          </Trait>
        </TraitSet>
        <Citation Type="general">
          <ID Source="PubMed">28492532</ID>
        </Citation>
        <SubmissionNameList>
          <SubmissionName>SUB4474525</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="3104745" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2021-05-10">
        <ClinVarSubmissionID localKey="NM_004380.2_16_Gain (exons 14-21)|MedGen:C0035934" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV001579142" DateUpdated="2024-06-09" DateCreated="2021-05-10" Type="SCV" Version="5" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2018-04-03">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">25640679</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">17052327</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">18792986</ID>
          </Citation>
          <Comment>This variant results in a copy number gain of the genomic region encompassing exons 14-21 of the CREBBP gene. While the exact position of this variant cannot be determined from this data, sub-genic copy number gains are generally in tandem (PMID: 25640679) and may result in an absent or disrupted protein product. Loss-of-function variants in CREBBP are known to be pathogenic (PMID: 17052327, 18792986). For these reasons, this variant has been classified as Pathogenic. This copy number gain has been observed to be de novo in an individual affected with clinical features of Rubinstein-Taybi syndrome (Invitae).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CREBBP" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000016.9:g.(?_3799608)_(3821007_?)dup</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0035934" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11431369</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
          <SubmissionName>SUB8755776</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="3104745" TraitType="Disease" MappingType="XRef" MappingValue="C0035934" MappingRef="MedGen">
        <MedGen CUI="C0035934" Name="Rubinstein-Taybi syndrome" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="1609062" TraitType="Disease" MappingType="Name" MappingValue="Rubinstein-Taybi syndrome" MappingRef="Preferred">
        <MedGen CUI="C0035934" Name="Rubinstein-Taybi syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

